The ARID4B Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal population of human T lymphoblasts with targeted disruption of the ARID4B gene. This loss-of-function model facilitates the study of ARID4B-dependent transcriptional repression and epigenetic regulation in a T cell leukemia background. The polyclonal format captures a range of editing outcomes, offering a biologically diverse cell pool for functional analyses without clonal selection.
The parental Jurkat cell line is an immortalized T lymphoblast line derived from a 14-year-old male with acute T cell leukemia. It serves as a well-established model for T lymphocyte signaling and leukemogenesis. These cells maintain key features of immature T cells and are widely employed to investigate proliferation, apoptosis, and immune response pathways. Using Jurkat cells as the host for ARID4B knockout allows dissection of the gene’s role in a disease-relevant cellular context.
ARID4B encodes a transcriptional corepressor that assembles with SIN3A and histone deacetylases HDAC1/2 to form a chromatin-remodeling complex. This complex mediates targeted histone deacetylation, leading to chromatin condensation and repression of genes driving cell cycle progression and survival. ARID4B is subject to regulation by the RB/E2F axis: RB1 restrains E2F transcription factors, which modulate ARID4B expression. Downstream targets include cyclin A2 (CCNA2), cyclin E1 (CCNE1), and CDK2, essential for G1/S transition. Interacting partners SIN3A, HDAC1, HDAC2, and RB1 position ARID4B at the intersection of epigenetic silencing and cell cycle control.
In Jurkat T lymphoblasts, ARID4B knockout provides a platform to interrogate how disruption of transcriptional corepression impacts leukemic phenotypes. The host cell line’s origin from acute T cell leukemia renders this model particularly relevant for studying oncogenic transformation. Researchers can examine how ARID4B loss influences proliferation, apoptosis, and drug sensitivity, potentially revealing synergistic effects with existing oncogenic lesions. The model also offers a means to investigate epigenetic therapy mechanisms, such as responses to HDAC inhibitors, in a corepressor-deficient background.
The product supports diverse experimental workflows. Western blotting and RT-qPCR confirm ARID4B disruption and quantify downstream target expression (e.g., CCNA2, CCNE1, CDK2). Proliferation (MTT) and apoptosis (Annexin V) assays assess phenotypic outcomes. Drug sensitivity profiling with HDAC inhibitors or chemotherapeutics can uncover therapeutic vulnerabilities. Chromatin immunoprecipitation-qPCR (ChIP-qPCR) enables evaluation of histone acetylation at ARID4B-regulated loci, while RNA-seq enables transcriptome profiling. These applications make the knockout pool a versatile tool for epigenetic and cancer studies. For further information, please contact Ascent Research.
